Disease · MONDO_0006314
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| MFNS vs Placebo: serious adverse events | 2 of 375 | 3 of 373 | 748 | NCT01386125 | Trial comparisons |
| Benra 30 mg vs Placebo: Percentage of Subjects With NP Surgery or SCS_NP | 72 of 207 | 91 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: Percentage of Subjects With NP Surgery | 33 of 207 | 37 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: deaths from any cause | 0 of 207 | 0 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: Percentage of Subjects With SCS_NP | 52 of 207 | 66 of 203 | 410 | NCT03401229 | Trial comparisons |
| Benra 30 mg vs Placebo: serious adverse events | 25 of 207 | 19 of 203 | 410 | NCT03401229 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP | 26 of 139 | 30 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery for CRSwNP | 8 of 139 | 10 of 135 | 274 | NCT04157335 | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With SCS Use for CRSwNP | 21 of 139 | 22 of 135 | 274 | NCT04157335 | Trial comparisons |
| Rimegepant vs Placebo: deaths from any cause | 0 of 99 | 0 of 105 | 204 | NCT05248997 | Trial comparisons |
| Rimegepant vs Placebo: serious adverse events | 0 of 99 | 0 of 105 | 204 | NCT05248997 | Trial comparisons |
| Treatment vs Control: deaths from any cause | 0 of 53 | 0 of 47 | 100 | NCT01732536 | Trial comparisons |
| Treatment vs Control: serious adverse events | 0 of 53 | 1 of 47 | 100 | NCT01732536 | Trial comparisons |
| Benralizumab Treatment Group vs Placebo Group: Number of Participants Who Dropped Out | 0 of 12 | 0 of 12 | 24 | NCT03450083 | Trial comparisons |
| Benralizumab Treatment Group vs Placebo Group: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT03450083 | Trial comparisons |
| Benralizumab Treatment Group vs Placebo Group: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT03450083 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006314/comparisons